Surveillance of Antimicrobial Consumption

In Primary Care

2025 Quarter 2

Key Points

  • The rate of antimicrobial consumption in primary care in Ireland for the second quarter of 2025 was 18.6 defined daily doses (DDD) per 1,000 inhabitants per day (DID). This represents a decrease from the second quarter of last year, when the consumption was recorded as 20.1 DID, and it is the lowest consumption recorded for the second quarter since 2021. This also brings the annual consumption in 2025 down to 20.1 DID.

  • The most notable increasing trend in recent years was observed in Tetracyclines (J01A). Tetracyclines have shown a consistent annual increase, reaching their highest level at 4.5 DID in the first quarter of 2025. In the second quarter of 2025, tetracycline consumption decreased to 3.8 DID, bringing the annual rate for 2025 down to 4.2 DID, which is the same annual rate as the previous year. This also represents a decrease from the second quarter of 2024, when tetracycline consumption was recorded as 4.2 DID.

  • A similar trend was observed for the consumption of Penicillins (J01C). The consumption of penicillins decreased to 8.9 DID, the lowest level for a second quarter since 2021. This brought the annual rate down to 9.8 DID, a decrease from 10.4 DID in the previous year. On the other hand, the consumption of Other Beta-Lactam Antibacterials (J01D) increased. Consumption in this group was recorded as 0.6 DID in the second quarter of 2024; however, it was recorded as 1.0 DID in the second quarter of 2025.

  • The consumption of Macrolides, Lincosamides and Streptogramins (J01F) has been fluctuating between 3.2 and 3.4 DID since quarter four of 2023. However, in the second quarter of 2025, consumption in this group saw a sharp decline and was recorded as 2.7 DID. This also brought the annual rate for 2025 down to 2.9 DID, a decrease from 3.3 DID in the previous year. This decrease was mainly driven by clarithromycin.

  • The consumption of Other Antibacterials (J01X) has been slowly decreasing over the last five years. Consumption was 1.4 DID in 2021 and has since decreased, reaching its lowest level in the last five years at 1.1 DID.


Methodology

Background

Antimicrobial consumption is the main driver of antimicrobial resistance. Therefore, antimicrobial consumption surveillance is important to identify potential over and inappropriate use of antimicrobial agents.

ATC/DDD Methodology

Irish antimicrobial sales data are obtained from IQVIA (formerly IMS Health), a pharmaceutical market research company. This dataset contains regional, monthly wholesaler-to-community pharmacy sales data from over 95% of the wholesalers and manufacturers in Ireland.

Consumption is measured as defined daily dose (DDD), which is the assumed average maintenance dose per day for a drug used for its main indication in adults. The WHO Anatomical Therapeutic Chemical (ATC) index is used to categorise antimicrobial agents. The ATC/DDD system is recommended by WHO as the international standard for drug utilization studies and it serves as a tool for drug utilization monitoring and research to improve quality of drug use. More information on ATC/DDD Methodology can be found on WHO’s website.

Consumption rates are calculated as DDD per 1000 inhabitants per day (DID). Eurostat yearly population estimates are used for national rates. Central Statistics Office 2022 Census results are proportionated with Eurostat population to calculate the county rates. The underlying trend on the quarterly graph is derived by using local regression of seasonal results.

The WHO introduced the AWaRe classification in 2017 as part of its Essential Medicines List to support antimicrobial stewardship activities. This system categorizes antibiotics into three groups—Access, Watch, and Reserve—to promote their responsible use. To assess the relative consumption of these categories, the 2023 AWaRe classification is applied. By 2030, the EU aims for at least 65% of total antibiotic consumption to come from the Access group in every Member State.

The European Surveillance of Antimicrobial Consumption Network (ESAC-Net) is managed by the European Centre for Disease Prevention and Control (ECDC) and the network uses the same methodology. The country rates for the EU Member States are obtained from ECDC’s ESAC-Net Dashboard. More information on ESAC-Net can be found on ECDC’s website.

Limitations

Although the IQVA database used in this report is very comprehensive, there are some limitations. The data are based on pharmacy wholesale data, rather than on individual prescriptions. Thus, it cannot be used to determine the actual number of antimicrobial courses taken and does not provide information on dose or duration of therapy. Factors such as stockpiling of antimicrobials in pharmacies and drug wastage (e.g. passing the sell-by date) may introduce biases. Likewise, recent changes to prescribing guidelines, that recommend using higher doses may lead to an increase in consumption (as measured by DDD/1000 inhabitants/day), while the total number of prescriptions may have remained static or even declined.


Main Results



Table 1: Antibiotic Consumption in the Last 5 Years by ATC-3 Groups

ATC-3 Name

2021

2022

2023

2024

2025

J01A Tetracyclines

3.0

3.8

3.9

4.2

4.2

J01C Beta-Lactam Antibacterials, Penicillins

7.2

10.4

10.5

10.4

9.8

J01D Other Beta-Lactam Antibacterials

1.0

1.3

0.5

0.8

1.1

J01E Sulfonamides and Trimethoprim

0.9

0.8

0.9

0.8

0.8

J01F Macrolides, Lincosamides and Streptogramins

2.5

3.4

3.1

3.3

2.9

J01M Quinolone Antibacterials

0.4

0.4

0.4

0.3

0.3

J01X Other Antibacterials

1.4

1.4

1.3

1.2

1.1

Total Consumption

16.3

21.5

20.6

21.0

20.1





Seasonal (Quarterly) Results



Table 2: Quarterly (Seasonal) Consumption of Antibiotics in the Last 5 Years

Year

Q1

Q2

Q3

Q4

Rate

2021

13.8

14.3

16.1

21.0

16.3

2022

18.7

19.9

18.2

29.1

21.4

2023

21.2

19.1

19.0

23.2

20.6

2024

21.6

20.1

19.2

23.3

21.0

2025

21.6

18.6

20.1



Tetracyclines



Table 3: Consumption of Tetracyclines (J01A) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2021

2.7

2.8

2.6

3.7

2022

3.8

3.8

3.1

4.6

2023

4.0

3.6

3.7

4.4

2024

4.4

4.2

3.7

4.5

2025

4.5

3.8


Penicillins



Table 4: Consumption of Penicillins (J01C) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2021

5.5

6.0

7.4

10.0

2022

8.3

9.2

8.7

15.2

2023

10.7

9.5

9.5

12.4

2024

10.8

9.8

9.0

12.0

2025

10.6

8.9


Other Beta-Lactams



Table 5: Consumption of Other Beta-Lactams (J01D) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2021

0.8

0.8

0.9

1.2

2022

1.1

1.2

1.1

1.9

2023

0.5

0.5

0.5

0.5

2024

0.6

0.6

0.9

1.1

2025

1.1

1.0


Macrolides



Table 6: Consumption of Macrolides (J01F) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2021

2.1

2.2

2.4

3.3

2022

2.9

3.2

2.8

4.6

2023

3.3

3.0

2.8

3.3

2024

3.2

3.3

3.2

3.4

2025

3.2

2.7


Quinolones



Table 7: Consumption of Quinolones (J01M) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2021

0.4

0.3

0.4

0.4

2022

0.4

0.4

0.4

0.4

2023

0.4

0.4

0.3

0.4

2024

0.4

0.3

0.3

0.3

2025

0.3

0.3


Results by Counties





Tetracyclines



Penicillins



Other Beta-Lactams



Macrolides



Quinolones



Results by CHOs and RHAs


Table 8: Overall Antibiotic Consumption in the Latest Year by CHO Areas

CHO Area

LHO Area

Q1

Q2

Q3

Q4

Rate

1

Donegal LHO, Sligo/Leitrim/West Cavan LHO and Cavan/Monaghan LHO

22.5

20.7

21.6

2

Galway LHO, Roscommon LHO and Mayo LHO

22.6

19.9

21.2

3

Clare LHO, Limerick LHO and North Tipperary/East Limerick LHO

26.0

21.7

23.9

4

Kerry LHO, North Cork LHO, North Lee LHO, South Lee LHO and West Cork LHO

22.6

19.3

21.0

5

South Tipperary LHO, Carlow/Kilkenny LHO, Waterford LHO and Wexford LHO

23.3

20.1

21.7

6

Wicklow LHO, Dún Laoghaire LHO and Dublin South East LHO

23.6

20.2

21.9

7

Kildare/West Wicklow LHO, Dublin West LHO, Dublin South City LHO and Dublin South West LHO

18.3

16.1

17.2

8

Laois/Offaly LHO, Longford/Westmeath LHO, Louth LHO and Meath LHO

22.6

18.9

20.7

9

Dublin North LHO, Dublin North Central LHO and Dublin North West LHO

19.1

16.6

17.8


Table 9: Overall Antibiotic Consumption in the Latest Year by RHAs

RHA

HSE Area

Q1

Q2

Q3

Q4

Rate

Area A

HSE Dublin & NE

20.1

17.1

18.6

Area B

HSE Dublin & Midlands

20.6

17.7

19.1

Area C

HSE Dublin & SE

23.1

19.9

21.5

Area D

HSE SW

22.6

19.3

21.0

Area E

HSE MW

26.0

21.7

23.9

Area F

HSE W & NW

22.4

20.3

21.4

Monthly Comparison


Tetracyclines



Penicillins



Other Beta-Lactams



Macrolides



Quinolones



International Comparison